Silence Therapeutics plc (SLN)

NASDAQ: SLN · IEX Real-Time Price · USD
25.54
0.00 (0.00%)
Feb 28, 2024, 2:19 PM EST - Market open
0.00%
Market Cap 952.05M
Revenue (ttm) 28.04M
Net Income (ttm) -42.62M
Shares Out 38.67M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 240,084
Open 25.42
Previous Close 25.54
Day's Range 25.00 - 26.70
52-Week Range 4.55 - 26.70
Beta 1.42
Analysts Strong Buy
Price Target 47.00 (+84.03%)
Earnings Date Mar 12, 2024

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company de... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Craig A. Tooman M.B.A.
Employees 122
Stock Exchange NASDAQ
Ticker Symbol SLN
Full Company Profile

Financial Performance

In 2022, SLN's revenue was $17.50 million, an increase of 40.97% compared to the previous year's $12.42 million. Losses were -$40.49 million, 2.74% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SLN stock is "Strong Buy." The 12-month stock price forecast is $47.0, which is an increase of 84.03% from the latest price.

Price Target
$47.0
(84.03% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

6 hours ago - Business Wire

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

5 days ago - Business Wire

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peo...

23 days ago - Business Wire

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

4 weeks ago - Business Wire

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

3 months ago - Business Wire

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

3 months ago - Business Wire

Silence Therapeutics to Present at Jefferies London Healthcare Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

4 months ago - Business Wire

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

4 months ago - Business Wire

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

5 months ago - Business Wire

Silence Therapeutics to Participate in September Investor Conferences

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming peop...

6 months ago - Business Wire

Silence Therapeutics Reports Second Quarter 2023 Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

7 months ago - Business Wire

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

8 months ago - Business Wire

Silence Therapeutics to Present at the Jefferies Healthcare Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

9 months ago - Business Wire

Silence Therapeutics Reports First Quarter 2023 Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

10 months ago - Business Wire

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

10 months ago - Business Wire

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

10 months ago - Business Wire

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

11 months ago - Business Wire

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

11 months ago - Business Wire

Silence Therapeutics to Present at Guggenheim's Genomic Medicines and Rare Disease Days

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics to Buyback siRNA Complement Assets

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peop...

1 year ago - Business Wire

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing...

1 year ago - Business Wire